Barratt DT - Search Results

1

Innate Immune Signalling Genetics of Pain, Cognitive Dysfunction and Sickness Symptoms in Cancer Pain Patients Treated with Transdermal Fentanyl.

Barratt DT, Klepstad P, Dale O, Kaasa S, Somogyi AA. Barratt DT, et al. PLoS One. 2015 Sep 2;10(9):e0137179. doi: 10.1371/journal.pone.0137179. eCollection 2015. PLoS One. 2015. PMID: 26332828 Free PMC article.

2

Genetic, pathological and physiological determinants of transdermal fentanyl pharmacokinetics in 620 cancer patients of the EPOS study.

Barratt DT, Bandak B, Klepstad P, Dale O, Kaasa S, Christrup LL, Tuke J, Somogyi AA. Barratt DT, et al. Pharmacogenet Genomics. 2014 Apr;24(4):185-94. doi: 10.1097/FPC.0000000000000032. Pharmacogenet Genomics. 2014. PMID: 24469018

3

Innate Immune and Neuronal Genetic Markers Are Highly Predictive of Postoperative Pain and Morphine Patient-Controlled Analgesia Requirements in Indian but Not Chinese or Malay Hysterectomy Patients.

Barratt DT, Sia AT, Tan EC, Somogyi AA. Barratt DT, et al. Pain Med. 2021 Nov 26;22(11):2648-2660. doi: 10.1093/pm/pnab172. Pain Med. 2021. PMID: 34015137

4

Pharmacogenetics of opioid response.

Somogyi AA, Coller JK, Barratt DT. Somogyi AA, et al. Among authors: barratt dt. Clin Pharmacol Ther. 2015 Feb;97(2):125-7. doi: 10.1002/cpt.23. Epub 2014 Dec 9. Clin Pharmacol Ther. 2015. PMID: 25670515

5

Pharmacogenetics of opioids.

Somogyi AA, Barratt DT, Coller JK. Somogyi AA, et al. Among authors: barratt dt. Clin Pharmacol Ther. 2007 Mar;81(3):429-44. doi: 10.1038/sj.clpt.6100095. Clin Pharmacol Ther. 2007. PMID: 17339873 Review.

6

Pharmacogenomics of methadone maintenance treatment.

Somogyi AA, Barratt DT, Ali RL, Coller JK. Somogyi AA, et al. Among authors: barratt dt. Pharmacogenomics. 2014 May;15(7):1007-27. doi: 10.2217/pgs.14.56. Pharmacogenomics. 2014. PMID: 24956254 Review.

7

Ethnicity-dependent influence of innate immune genetic markers on morphine PCA requirements and adverse effects in postoperative pain.

Somogyi AA, Sia AT, Tan EC, Coller JK, Hutchinson MR, Barratt DT. Somogyi AA, et al. Among authors: barratt dt. Pain. 2016 Nov;157(11):2458-2466. doi: 10.1097/j.pain.0000000000000661. Pain. 2016. PMID: 27649267

8

CYP2C8 Genotype Significantly Alters Imatinib Metabolism in Chronic Myeloid Leukaemia Patients.

Barratt DT, Cox HK, Menelaou A, Yeung DT, White DL, Hughes TP, Somogyi AA. Barratt DT, et al. Clin Pharmacokinet. 2017 Aug;56(8):977-985. doi: 10.1007/s40262-016-0494-0. Clin Pharmacokinet. 2017. PMID: 27995529

9

CYP3A5*3 and ABCB1 61A>G Significantly Influence Dose-adjusted Trough Blood Tacrolimus Concentrations in the First Three Months Post-Kidney Transplantation.

Hu R, Barratt DT, Coller JK, Sallustio BC, Somogyi AA. Hu R, et al. Among authors: barratt dt. Basic Clin Pharmacol Toxicol. 2018 Sep;123(3):320-326. doi: 10.1111/bcpt.13016. Epub 2018 May 7. Basic Clin Pharmacol Toxicol. 2018. PMID: 29603629 Free article.

10

Effect of tacrolimus dispositional genetics on acute rejection in the first 2 weeks and estimated glomerular filtration rate in the first 3 months following kidney transplantation.

Hu R, Barratt DT, Coller JK, Sallustio BC, Somogyi AA. Hu R, et al. Among authors: barratt dt. Pharmacogenet Genomics. 2019 Jan;29(1):9-17. doi: 10.1097/FPC.0000000000000360. Pharmacogenet Genomics. 2019. PMID: 30489455

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

30 results

Search Page